Baseline value and longitudinal kinetics of circulating nucleosomes during neo-adjuvant chemotherapy in newly diagnosed ovarian cancer: Results from the randomized phase II trial CHIVA (GINECO).

• DOI: 10.1200/jco.2024.42.16_suppl.e15029
• Publication Date: 2024-06-04T20:15:36Z
• Authors: Pauline Corbaux; Olivier Colomban; Gaelle Lescuyer; Christine Haon; Isabelle Laure Ra...; Gaetan De Rauglaudre; Florence Joly; Cyril Abdeddaim; Pierre Combe; Alain Lortholary; Salima Hamizi; Clothilde Deldycke; Gwenael Ferron; Jérôme Meunier; Jerome Alexandre; Dominique Berton-...; Marie-Christine K...; Eric Pujade-Lauraine; Lea Payen; Benoit You
• Keywords: Adjuvant Chemotherapy

e15029 Background: Nucleosomes (DNA wound around histone proteins) were reported as potential cancer biomarkers (1). The links between circulating nucleosomes and clinical endpoints in advanced ovarian (OC) patients treated with neo-adjuvant chemotherapy (NACT) +/- interval debulking surgery (IDS) retrospectively assessed the randomized phase II CHIVA trial (2). Methods: diagnostic concentration longitudinal kinetics of 2 (H3K27 H3K36, log-scale) investigated at baseline, during NACT, after IDS, progression. baseline titer measured Nu.Q prototype immunoassays (H3K27Me3, H3K36Me3 (Belgian Volition SRL, Belgium)) was compared to those a cohort 201 cancer-free subjects. Their prognostic values regarding probability obtaining complete IDS progression-free survival (PFS) respect modeled CA-125 KELIM (3), classical covariates treatment arms. maximum selected rank statistics used determine optimal cut-off different disease management times. Results: H3K27 H3K36 nucleosome concentrations available for 148/188 patients. correlated significantly higher OC subjects (H3K36, 2.8 vs 2.4 ng/mL, P<0.0001; H3K27, 3.2 2.1, P<0.0001), without difference according BRCA status. an independent predictor completeness (OR=0.33; 95% CI=0.13-0.71, p=0.009). independently associated PFS (< or ≥3.8 HR=1.84, 95%CI=1.11-3.02, p=0.016), complementary KELIM. Both showed decrease but there no significant statistical association their radiological response rate, PFS. Conclusions: Baseline could represent non-invasive method detecting OC, relevant value initial titers newly diagnosed 1. McAnena, Cancers 2017. 2. Ferron, Gynecol Oncol 2023. 3. You, CCR 2020.